Ingrid joined Amgen in 2005 as scientist, specializing in islet biologist to support type 2 diabetes programs. Prior to joining Amgen, Ingrid received her B.A. in psychobiology from University of California, Santa Cruz. After college, Ingrid spent 3 years working in the laboratory of Hugh McDevitt, an immunology pioneer at Stanford University. This experience led her to graduate school at the University of Chicago where she received her doctorate in immunology under the mentorship of Jeffrey Bluestone; areas of focus included the role of costimulatory molecules in immune tolerance, autoimmune disease processes and graft rejection. During her postdoctoral training, first at University of California, San Francisco and then Stanford, Ingrid transitioned into studying stem cell biology and pancreas development, extending her interest in type 1 diabetes from disease pathogenesis into therapeutic discovery.
With over 30 years of hands-on experience in the laboratory, including both in vitro and in vivo biology, Ingrid has managed and contributed to programs spanning a variety of disease areas, including obesity, chronic kidney disease, non-alcoholic fatty liver disease, and now heart failure. Ingrid has a strong interest in the development and advancement of RNA therapeutics; she initiated the PNPLA3 siRNA program which led to AMG 609, Amgen's first homegrown siRNA therapeutic to enter the clinic. Currently she is leading hepatic siRNA programs and supporting the development of extrahepatic siRNA therapeutics and mRNA capacity at Amgen. Ingrid is also involved in Human Data initiatives, invested in partnering with Amgen and deCODE colleagues, and external collaborators, to advance the success of therapeutic programs by applying human genetics and multiomic data analysis.
Murray JK, Long J, Liu L, Singh S, Pruitt D, Ollmann M, Swearingen E, Hardy M, Homann O, Wu B, Holder JR, Sham K, Herberich B, Lo MC, Dou H, Shkumatov A, Florio M and Rulifson IC (2021) Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease. Nucleic Acid Ther 31:324-340. doi: 10.1089/nat.2021.0026
Rulifson IC, Collins P, Miao L, Nojima D, Lee KJ, Hardy M, Gupte J, Hensley K, Samayoa K, Cam C, Rottman JB, Ollmann M, Richards WG and Li Y (2017) In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator. J Biol Chem 292:1951-1969. doi: 10.1074/jbc.M116.751404
Rulifson IC, Cao P, Miao L, Kopecky D, Huang L, White RD, Samayoa K, Gardner J, Wu X, Chen K, Tsuruda T, Homann O, Baribault H, Yamane H, Carlson T, Wiltzius J and Li Y (2016) Identification of Human Islet Amyloid Polypeptide as a BACE2 Substrate. PLoS One 11:e0147254. doi: 10.1371/journal.pone.0147254
Rulifson IC, Majeti JZ, Xiong Y, Hamburger A, Lee KJ, Miao L, Lu M, Gardner J, Gong Y, Wu H, Case R, Yeh WC, Richards WG, Baribault H and Li Y (2014) Inhibition of secreted frizzled-related protein 5 improves glucose metabolism. Am J Physiol Endocrinol Metab 307:E1144-52. doi: 10.1152/ajpendo.00283.2014
Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, Taketo MM, Nusse R, Hebrok M and Kim SK (2007) Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 104:6247-52. doi: 10.1073/pnas.0701509104
Postdoctoral Fellowship, Stanford University
Postdoctoral Fellowship, University of California, San Francisco
Ph.D., University of Chicago
B.A., University of California, Santa Cruz